We are live on ! Find out more
TA

Tamarack Advisers Portfolio holdings

AUM $2.12M
1-Year Est. Return 58.09%
This Fund
S&P 500
This Quarter Est. Return
+25.06%
1 Year Est. Return
-58.09%
3 Year Est. Return
-46.51%
5 Year Est. Return
+44.44%
10 Year Est. Return
–
AUM
$252M
AUM Growth
+$6.65M
Cap. Flow
-$26.7M
Cap. Flow %
-10.6%
Top 10 Hldgs %
83.32%
Holding
28
New
7
Increased
8
Reduced
5
Closed
6

Top Buys

Rank Stock Value
1
PCRX icon
Pacira BioSciences
PCRX
+$12.5M
2
PTLA
Portola Pharmaceuticals, Inc.
PTLA
+$9.38M
3
NVRO
NEVRO CORP.
NVRO
+$7.52M
4
MDT icon
Medtronic
MDT
+$6.71M
5
MDRX
Veradigm Inc. Common Stock
MDRX
+$5.52M

Top Sells

Rank Stock Value
1
NUVA
NuVasive, Inc.
NUVA
+$24.8M
2
NVCR icon
NovoCure
NVCR
+$22.4M
3
NXTM
NxStage Medical Inc.
NXTM
+$17.9M
4
SCI icon
Service Corp International
SCI
+$6.47M
5
MCK icon
McKesson
MCK
+$5.52M

Sector Composition

Rank Sector Weight
1 Healthcare 76.86%
2 Industrials 11.02%
3 Consumer Discretionary 1.91%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
NUVA
26
DELISTED
NuVasive, Inc.
NUVA
– –
-500,000
Closed -$24.8M
PTLA
27
CALL
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
– –
-3,500
Closed -$175K
NXTM
28
DELISTED
NxStage Medical Inc.
NXTM
– –
-625,000
Closed -$17.9M
1
2

Similar funds

SCM
SevenOneSeven Capital Management Lancaster, Pennsylvania $2.17M AUM 8.67% 1-Year Est. Return
LBC
Lawrence B. Cohen $2.06M AUM 34.47% 1-Year Est. Return
ICM
ISZO Capital Management New York $2M AUM 35.61% 1-Year Est. Return
LCMP
Linse Capital Management PR San Juan, Puerto Rico $2.31M AUM
GIP
General Industrial Partners London, United Kingdom $2.57M AUM
STC
Sarah T. Connolly $1.11M AUM 24.13% 1-Year Est. Return
GC
Gilfoyle & Co San Francisco, California $671K AUM
DU
Delphia (USA) Toronto, Ontario, Canada $445K AUM 28.82% 1-Year Est. Return

Tamarack Advisers's Q1 2019 Portfolio in Review

As of Q1 2019, Tamarack Advisers held 28 positions worth $252M, up 2.7% from $245M the previous quarter. Its ten largest holdings account for 83% of the portfolio.

Tamarack Advisers withdrew a net $26.7M in Q1 2019, closing 6 positions and reducing 5 holdings. Its most notable exit was NuVasive, Inc., an estimated $24.8M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 77% of assets, down from 85% a quarter earlier, followed by Industrials and Consumer Discretionary.

Against the trend, Tamarack Advisers opened a new position in Pacira BioSciences worth $12.2M.

  • Tamarack Advisers's largest Q1 2019 buy was Pacira BioSciences: 320,000 shares worth $12.2M.
  • Tamarack Advisers added most to Portola Pharmaceuticals, Inc. in Q1 2019, an estimated $9.38M increase.
  • Tamarack Advisers's biggest Q1 2019 reduction was Service Corp International, cutting an estimated $6.47M.
  • Tamarack Advisers fully exited NuVasive, Inc. in Q1 2019, selling an estimated $24.8M.
  • Tamarack Advisers's ten largest holdings make up 83% of its $252M portfolio in Q1 2019.
  • Tamarack Advisers opened 7 new positions and closed 6 in Q1 2019.
  • Tamarack Advisers's portfolio value rose 2.7% quarter-over-quarter to $252M.

Based on Tamarack Advisers's 13F filing for Q1 2019, filed 13 May 2019.